TED-347


CAS No. : 2378626-29-8

2378626-29-8
Price and Availability of CAS No. : 2378626-29-8
Size Price Stock
1mg $110 In-stock
5mg $143 In-stock
10mg $200 In-stock
25mg $400 In-stock
50mg $600 In-stock
100mg $860 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-125269
M.Wt: 313.70
Formula: C15H11ClF3NO
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 2378626-29-8 :

TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4?Yap1 protein-protein interaction. TED-347 specifically and covalently bonds with Cys-367 within the central pocket of TEAD4 with a Ki of 10.3 μM. TED-347 blocks TEAD transcriptional activity and has antitumor activity[1]. IC50 & Target: IC50: 5.9 μM (TEAD4?Yap1 protein-protein interaction)[1] In Vitro: TED-347 (0.5-100 μM; 48 hours) inhibits GBM43 cancer cell viability[1].
TED-347 (5 μM; 48 hours) inhibits co-immunoprecipitation of Myc-tagged TEAD4 with FLAG-tagged Yap1[1].
TED-347 (10 μM; 48 hours) shows a significant reduction in CTGF transcript levels[1].
TED-347 (0.5-100 μM; 24 hours) reduces reporter activity in cells transfected with a TEAD reporter. TED-347 (0.5-100 μM) also inhibits TEAD4 transcriptional activity in GBM43 cells[1].
TED-347 is selective for TEADs and inhibits TEAD2 with the same efficacy. TED-347 (0.1-100 μM; 24-48 hours) inhibits TEAD4 binding to full-length Yap1 in dose- and time-dependent manner. TED-347 (1-100 μM) shows no inhibition of uPAR?uPA or Cav2.2 α?β protein-protein interactions. Non-covalent binding of TED-347 to TEAD4 exhibits little change to the TEAD4?Yap1 binding affinity[1].
TED-347 has the maximum rate of inactivation of 0.038 hours, corresponding to a t1/2 of 18.2 hours[1].

Your information is safe with us.